TICKERNOMICS Sign up
Last Update: 2024-03-28 02:16:05
ReShape Lifesciences Inc. ( RSLS ) https://www.reshapelifesciences.com
0.18USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-94.17%
RSLS
SPY
32.74%
-99.96%
RSLS
SPY
92.93%
-99.99%
RSLS
SPY
224.41%
-99.00%
RSLS
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
0.61
-0.55
0.30
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.02
0.06
0.20
-2425.10
0.00
0.02
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-143.99
59.77
-227.52
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.0675
-328.12
-353.67
0.75
Other Earnings and Cash Flow Stats:
ReShape Lifesciences Inc. ( RSLS ) Net Income TTM ($MM) is -48.57
ReShape Lifesciences Inc. ( RSLS ) Operating Income TTM ($MM) is -10.27
ReShape Lifesciences Inc. ( RSLS ) Owners' Earnings Annual ($MM) is -15.33
ReShape Lifesciences Inc. ( RSLS ) Current Price to Owners' Earnings ratio is -0.04
ReShape Lifesciences Inc. ( RSLS ) EBITDA TTM ($MM) is -16.46
ReShape Lifesciences Inc. ( RSLS ) EBITDA Margin is -227.52%
Capital Allocation:
ReShape Lifesciences Inc. ( RSLS ) has paid 0.00 dividends per share and bought back -3.028282 million shares in the past 12 months
ReShape Lifesciences Inc. ( RSLS ) has reduced its debt by 0.242 million USD in the last 12 months
Capital Structure:
ReShape Lifesciences Inc. ( RSLS ) Interest-bearing Debt ($MM) as of last quarter is 0
ReShape Lifesciences Inc. ( RSLS ) Annual Working Capital Investments ($MM) are 7
ReShape Lifesciences Inc. ( RSLS ) Book Value ($MM) as of last quarter is 3
ReShape Lifesciences Inc. ( RSLS ) Debt/Capital as of last quarter is 9%
Other Balance Sheet Stats:
ReShape Lifesciences Inc. ( RSLS ) has 1 million in cash on hand as of last quarter
ReShape Lifesciences Inc. ( RSLS ) has 4 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ReShape Lifesciences Inc. ( RSLS ) has 3 common shares outstanding as of last quarter
ReShape Lifesciences Inc. ( RSLS ) has 0 million USD of preferred stock value
Academic Scores:
ReShape Lifesciences Inc. ( RSLS ) Altman Z-Score is -117.89 as of last quarter
ReShape Lifesciences Inc. ( RSLS ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
ReShape Lifesciences Inc. ( RSLS ) largest shareholder is Advisor Group Holdings, Inc. owning 10 shares at 0.00 ($MM) value
Thomas Stankovich(an insider) Sold 131 shares of ReShape Lifesciences Inc. ( RSLS ) for the amount of $35.37 on 2023-10-25
5.68% of ReShape Lifesciences Inc. ( RSLS ) is held by insiders, and 5.75% is held by institutions
ReShape Lifesciences Inc. ( RSLS ) went public on 2007-11-15
Other ReShape Lifesciences Inc. ( RSLS ) financial metrics:
FCF:-13.94
Unlevered Free Cash Flow:-30.15
EPS:-4.09
Operating Margin:-143.99
Gross Profit Margin:59.77
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-458.51
Beta:0.75
Buffet's Owners Earnings:-15.33
Price to Owner's Earnings:-0.04
About ReShape Lifesciences Inc. ( RSLS ) :
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.